Berlin-Brandenburg at BIO 2024
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Berlin</strong>-<strong>Brandenburg</strong> Pavilion<br />
<strong>BIO</strong> <strong>2024</strong><br />
THE GERMAN CAPITAL REGION<br />
excellence in life sciences & healthcare
2<br />
3<br />
Joint Pavilion of the German Capital Region <strong>Berlin</strong>-<strong>Brandenburg</strong><br />
HealthCapital <strong>Berlin</strong>-<strong>Brandenburg</strong><br />
-09 -10 -11 -12<br />
-08<br />
-13<br />
-14<br />
-07<br />
Block 4217<br />
Inform<strong>at</strong>ion .................................... 4217-07<br />
<strong>Berlin</strong> Partner for Business und<br />
Technology .................................... 4217-07<br />
biotechrabbit GmbH ....................... 4217-08<br />
Campus <strong>Berlin</strong>-Buch GmbH ........... 4217-14<br />
CPL Sachse GmbH ........................ 4217-09<br />
Cinference GmbH .......................... 4217-13<br />
Economic Development Agency<br />
<strong>Brandenburg</strong> (WFBB) .................... 4217-07<br />
FyoniBio GmbH .............................. 4217-12<br />
HealthCapital <strong>Berlin</strong>-<strong>Brandenburg</strong> . 4217-07<br />
IGES Institut GmbH ....................... 4217-10<br />
NUVISAN ..................................... 4217-07<br />
pharmtrace klinische Entwicklung<br />
GmbH ........................................... 4217-11<br />
The Healthcare Industries Cluster <strong>Berlin</strong>-<br />
<strong>Brandenburg</strong> – HealthCapital – is one of the<br />
leading life sciences and healthcare centers<br />
in the world. The unique research and clinic<br />
landscape, which is the region‘s major<br />
strength, is supported by a close network of<br />
key players from research, clinics and industry.<br />
Here, numerous technology parks and<br />
networks in different fields, above all biotechnology<br />
and medical technology, cre<strong>at</strong>e an<br />
excellent infrastructure for transforming the<br />
l<strong>at</strong>est scientific findings into innov<strong>at</strong>ive products<br />
and services for the healthcare sector.<br />
The German Capital Region is also a leading<br />
center of the IT industry. Th<strong>at</strong> combin<strong>at</strong>ion<br />
offers optimal conditions for the development<br />
of innov<strong>at</strong>ive digital health solutions for the<br />
regional and global market. <strong>Berlin</strong> Partner<br />
for Business and Technology is responsible<br />
for managing the cluster in cooper<strong>at</strong>ion<br />
with the Economic Development Agency<br />
<strong>Brandenburg</strong> (WFBB).<br />
HealthCapital <strong>Berlin</strong>-<strong>Brandenburg</strong> c/o <strong>Berlin</strong><br />
Partner für Wirtschaft und Technologie GmbH<br />
Fasanenstr. 85<br />
10623 <strong>Berlin</strong> | Germany<br />
Carolin Clement<br />
Tel. +49 30 463 02-463<br />
info@healthcapital.de<br />
www.healthcapital.de
4<br />
5<br />
<strong>Berlin</strong> Partner for Business and Technology<br />
biotechrabbit GmbH<br />
First Choice: <strong>Berlin</strong> Partner for Business<br />
and Technology<br />
Business and technology support for companies,<br />
investors and scientific institutions in<br />
<strong>Berlin</strong> – this is the <strong>Berlin</strong> Partner für<br />
Wirtschaft und Technologie GmbH mission.<br />
With customized services and an excellent<br />
science and research network, our many<br />
experts provide an outstanding range<br />
of programs to help companies launch,<br />
innov<strong>at</strong>e, expand and secure their economic<br />
future in <strong>Berlin</strong>.<br />
A unique public-priv<strong>at</strong>e partnership, <strong>Berlin</strong><br />
Partner for Business and Technology<br />
collabor<strong>at</strong>es with the <strong>Berlin</strong> St<strong>at</strong>e Sen<strong>at</strong>e<br />
and more than 250 companies dedic<strong>at</strong>ed<br />
to promoting their city. <strong>Berlin</strong> Partner is also<br />
responsible for marketing the German capital<br />
to the world.<br />
biotechrabbit GmbH, based in <strong>Berlin</strong>, Germany,<br />
is a leading manufacturer in the field of molecular<br />
biology, providing high-performance<br />
enzymes, antibodies, and reagents for diagnostics,<br />
life sciences research, and applied<br />
markets. We are <strong>at</strong> the forefront of cell-free<br />
protein synthesis with our Rapid Transl<strong>at</strong>ion<br />
System (RTS) kits, supporting biopharma<br />
companies, and provide therapeutic proteins<br />
for Gene Silencing, fe<strong>at</strong>uring Cas9 and<br />
Cas12 enzymes. We also support mRNA<br />
therapeutics with crucial proteins like T7<br />
RNA Polymerase and RNase Inhibitor.<br />
adhering to ISO 13485 and ISO 9001 standards.<br />
At biotechrabbit, we strive to exceed<br />
industry standards with innov<strong>at</strong>ive and flexible<br />
solutions tailored to the unique needs of<br />
our partners.<br />
Our team, driven by the curiosity of top-tier<br />
researchers and the agility of seasoned<br />
entrepreneurs, is committed to helping our<br />
partners and customers achieve significant<br />
advancements in life science.<br />
Our production process is robust, involving<br />
high-density ferment<strong>at</strong>ion, meticulous purific<strong>at</strong>ion,<br />
and stringent quality control, all while<br />
<strong>Berlin</strong> Partner für Wirtschaft<br />
und Technologie GmbH<br />
Fasanenstr. 85<br />
10623 <strong>Berlin</strong> | Germany<br />
Susan Kaffenberger<br />
Tel. +49 30 463 02 - 295<br />
susan.kaffenberger@berlin-partner.de<br />
www.berlin-partner.de<br />
biotechrabbit GmbH<br />
Volmerstr. 9<br />
12489 <strong>Berlin</strong> | Germany<br />
Dr. Bernd Haase<br />
Tel. +49 30 5557 8210<br />
info@biotechrabbit.com<br />
www.biotechrabbit.com
6<br />
7<br />
Campus <strong>Berlin</strong>-Buch GmbH<br />
CPL Sachse GmbH<br />
Interaction of Research, Clinics and<br />
Companies<br />
<strong>Berlin</strong>-Buch is the loc<strong>at</strong>ion of one of the<br />
largest biotechnology parks in Germany, with<br />
45,000 square meters of scalable lab and<br />
office space for start-ups and companies.<br />
Situ<strong>at</strong>ed to the northeast of the city, the<br />
Campus <strong>Berlin</strong>-Buch is currently home to<br />
78 companies, 57 of which are biotech<br />
companies; the rest provides support<br />
services. Part of the Campus community<br />
are the Max Delbrück Center for Molecular<br />
Medicine, the Leibniz Institute for Molecular<br />
Pharmacology, as well as clinical groups<br />
from the Charité University Medicine <strong>Berlin</strong><br />
and the <strong>Berlin</strong> Institute of Health.<br />
dedic<strong>at</strong>ed to health<br />
CPL Sachse produces APIs for human<br />
and veterinary use.<br />
We manufacture APIs under cGMP for (pre-)<br />
clinical development and market supply up<br />
to ≤ 50 kg scale. The company has been<br />
successfully inspected multiple times by<br />
EMA (LaGeSo) and FDA.<br />
The following compounds are available<br />
from us under a GMP certific<strong>at</strong>e from our<br />
local authority: Anagrelide, Atipamezole,<br />
Clenbuterol (CEP), Detomidine (CEP),<br />
Medetomidine, Methacetin( 13 C), Nabilone<br />
and Phenoxybenzamine. Further APIs as<br />
well as reference standards for APIs and<br />
impurities are available on request.<br />
Moreover, we carry our route scouting for<br />
NCEs and develop and valid<strong>at</strong>e processes<br />
as well as analytical methods required to<br />
test the APIs and the subsequent drug<br />
products. Furthermore, we offer stability<br />
tests according to ICH guidelines.<br />
Finally, we offer all regul<strong>at</strong>ory services<br />
required for the prepar<strong>at</strong>ion and submission<br />
of a pharmaceutical dossier (for APIs and<br />
drug products).<br />
SMART API ® CHEMISTRY + DEVELOPMENT<br />
Campus <strong>Berlin</strong>-Buch GmbH<br />
Robert-Rössle-Str. 10<br />
13125 <strong>Berlin</strong> | Germany<br />
Dr. Christina Quensel<br />
Tel. +49 30 9489 2511<br />
office@campusberlinbuch.de<br />
www.campusberlinbuch.de<br />
Chemisch-pharmazeutisches Labor,<br />
Rolf Sachse GmbH<br />
Stiefring 14<br />
13627 <strong>Berlin</strong> | Germany<br />
Dr. Michael Sefkow<br />
Tel. +49 173 373 2260<br />
michael.sefkow@cpl-sachse.de<br />
www.cpl-sachse.de
8<br />
9<br />
Economic Development Agency <strong>Brandenburg</strong> (WFBB)<br />
FyoniBio GmbH<br />
The Economic Development Agency<br />
<strong>Brandenburg</strong> (WFBB) is the central point of<br />
contact for investors, companies based in<br />
the st<strong>at</strong>e of <strong>Brandenburg</strong> and technologyoriented<br />
start-ups. WFBB offers a broad<br />
array of services for economic development<br />
and the promotion of employment: From<br />
supporting a company‘s establishment and<br />
its expansion to promoting innov<strong>at</strong>ions,<br />
intern<strong>at</strong>ionaliz<strong>at</strong>ion and networking as well<br />
as the acquisition and qualific<strong>at</strong>ion of a<br />
skilled workforce. As <strong>Brandenburg</strong>‘s Energy<br />
Agency, WFBB is also closely linked to<br />
the implement<strong>at</strong>ion of the st<strong>at</strong>e‘s energy<br />
str<strong>at</strong>egy. Furthermore, we support the<br />
development of sector-specific innov<strong>at</strong>ion<br />
clusters in the st<strong>at</strong>e of <strong>Brandenburg</strong> and the<br />
German Capital Region.<br />
FyoniBio provides ISO-9001 compliant<br />
contract development services solutions for<br />
supporting the customers in their biopharma<br />
development program.<br />
Our offerings include:<br />
• Cell line development in human, GEX ®<br />
and CHO based pl<strong>at</strong>forms<br />
• USP development, DSP development,<br />
analytical development<br />
• In depth PTM and protein analytics (Nand<br />
O-glyco-profiling, further PTM, sequence<br />
confirm<strong>at</strong>ion and identific<strong>at</strong>ion)<br />
• Bioassay development services for different<br />
stages of drug development (Cell<br />
viability & cytotoxicity, immuno-oncology)<br />
• Clinical Bioassay service (Immunogenicity<br />
assays, PK/PD assessment, under<br />
GCLP)<br />
Wirtschaftsförderung Land<br />
<strong>Brandenburg</strong> GmbH<br />
Babelsberger Str. 21<br />
14473 Potsdam | Germany<br />
Stefan Bauer<br />
Tel. +49 331 730 61 - 251<br />
stefan.bauer@wfbb.de<br />
www.wfbb.de<br />
FyoniBio GmbH<br />
Robert-Rössle-Str. 10<br />
13125 <strong>Berlin</strong> | Germany<br />
Tel. +49 30 9489 2500<br />
contact@fyonibio.com<br />
www.fyonibio.com
10 11<br />
IGES Institut GmbH<br />
NUVISAN<br />
IGES supports biopharma companies on<br />
all issues rel<strong>at</strong>ed to market access and<br />
reimbursement for innov<strong>at</strong>ive therapies in<br />
Europe. With offices in Germany, France,<br />
the United Kingdom, the Netherlands and<br />
Switzerland, we provide comprehensive<br />
support on all leading European countries.<br />
We assist in all steps necessary for<br />
reimbursement including the HTA procedures<br />
of the European countries. This enables a<br />
seamless market entry in Europe. We take<br />
an analytical approach to commercializ<strong>at</strong>ion.<br />
The l<strong>at</strong>est tools, techniques and our in-depth<br />
knowledge of European healthcare are the<br />
found<strong>at</strong>ions of our work.<br />
The result: solutions th<strong>at</strong> work flawlessly in<br />
practice and are based on highly accur<strong>at</strong>e<br />
evidence.<br />
The NUVISAN group is a contract research<br />
and development and manufacturing<br />
organiz<strong>at</strong>ion (CRO/CDMO) with five sites in<br />
Germany and France as well as local experts<br />
situ<strong>at</strong>ed in L<strong>at</strong>in America. We offer unique,<br />
high-quality, and tailored integr<strong>at</strong>ed solutions<br />
along the drug discovery and development<br />
value chain to our biotech startup, pharma,<br />
non-profit, and venture capital clients – from<br />
target identific<strong>at</strong>ion to the p<strong>at</strong>ient.<br />
Thanks to more than 40 years of experience<br />
and about 1,000 employees (incl. > 70 %<br />
industry experienced scientists and lab<br />
professionals), we know how to discover,<br />
develop, and bring the next gener<strong>at</strong>ion<br />
medicines to market. At the same time, our<br />
scientists understand th<strong>at</strong> every project<br />
is different. With a flexible and innov<strong>at</strong>ive<br />
approach and transparent communic<strong>at</strong>ion,<br />
our teams are passion<strong>at</strong>e about closely<br />
collabor<strong>at</strong>ing with you to adapt to your<br />
individual needs.<br />
Our services can be provided as standalone<br />
or integr<strong>at</strong>ed solutions and can be<br />
customized to your project.<br />
IGES Institut GmbH<br />
Friedrichstr. 180<br />
10117 <strong>Berlin</strong> | Germany<br />
Dr. Tilo Mandry<br />
Tel. +49 30 230 809 0<br />
intern<strong>at</strong>ional@iges.com<br />
pharma.iges.com<br />
NUVISAN<br />
Muellerstr. 178<br />
13353 <strong>Berlin</strong> | Germany<br />
Carmen Diez Fernandez, William Thomas<br />
Tel. +33 621 967 584<br />
Carmen.DiezFernandez@nuvisan.com<br />
William.Thomas@nuvisan.com<br />
www.nuvisan.com
12<br />
pharmtrace klinische Entwicklung GmbH<br />
Independent end-to-end support for imaging<br />
studies, from protocol writing to interpreting<br />
the results to reporting. Our focus is on the<br />
defensibility and relevance of the imaging<br />
read-out in decision making discussions<br />
addressing developmental and regul<strong>at</strong>ory<br />
milestones for FDA and EMA. We also deliver<br />
expertise in assessing imaging procedures<br />
in the context of specific therapeutic areas<br />
and multiple clinical trial designs including<br />
medical device studies. ERICA, our image<br />
management pl<strong>at</strong>form, allows quality,<br />
consistency and robustness for all clinical<br />
trial imaging and rel<strong>at</strong>ed processes.<br />
pharmtrace klinische Entwicklung GmbH<br />
Wolframstr. 93 - 94<br />
12105 <strong>Berlin</strong> | Germany<br />
Antje Hoppenheit<br />
Tel. +49 163 405 0602<br />
info@pharmtrace.com<br />
www.pharmtrace.com
13<br />
The joint present<strong>at</strong>ion of the German Capital Region is hosted by the local economic<br />
authorities of the st<strong>at</strong>es of <strong>Berlin</strong> and <strong>Brandenburg</strong>:<br />
Sen<strong>at</strong>e Department for Economics,<br />
Energy and Public Enterprises<br />
Ministry for Economic Affairs,<br />
Labour and Energy<br />
managed by:<br />
<strong>Berlin</strong> Partner for Business and<br />
Technology<br />
Fasanenstr 85<br />
10623 <strong>Berlin</strong> | Germany<br />
David Blumenthal<br />
Tel. +49 30 46302-452<br />
david.blumenthal@berlin-partner.de<br />
supported by:<br />
© <strong>2024</strong> Booklet<br />
„<strong>Berlin</strong>-<strong>Brandenburg</strong> Pavilion“ <strong>at</strong> <strong>BIO</strong> <strong>2024</strong><br />
edited by: <strong>Berlin</strong> Partner für Wirtschaft und Technologie GmbH
Change language